BIOLINERX Ltd/S (NASDAQ:BLRX) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.06) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.06), Morningstar.com reports.
Shares of NASDAQ BLRX traded down $0.01 during trading on Friday, hitting $0.70. The stock had a trading volume of 391,694 shares, compared to its average volume of 1,728,884. BIOLINERX Ltd/S has a 12 month low of $0.67 and a 12 month high of $1.84. The firm has a market cap of $78.77 million, a price-to-earnings ratio of -2.59 and a beta of 0.87.
A number of analysts have commented on BLRX shares. HC Wainwright set a $4.00 price target on shares of BIOLINERX Ltd/S and gave the company a “buy” rating in a research note on Wednesday, October 3rd. ValuEngine upgraded shares of BIOLINERX Ltd/S from a “hold” rating to a “buy” rating in a research note on Thursday, October 4th. Zacks Investment Research upgraded shares of BIOLINERX Ltd/S from a “hold” rating to a “buy” rating and set a $1.00 price target for the company in a research note on Thursday, August 16th. Maxim Group restated a “buy” rating and set a $2.00 price target on shares of BIOLINERX Ltd/S in a research note on Monday, August 13th. Finally, MED started coverage on shares of BIOLINERX Ltd/S in a research note on Wednesday, August 1st. They set a “market perform” rating for the company. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $2.50.
ILLEGAL ACTIVITY NOTICE: “BIOLINERX Ltd/S (BLRX) Announces Earnings Results” was originally posted by WKRB News and is the property of of WKRB News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.wkrb13.com/2018/11/10/biolinerx-ltd-s-blrx-announces-earnings-results.html.
BIOLINERX Ltd/S Company Profile
BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
Further Reading: S&P 500 Index
Receive News & Ratings for BIOLINERX Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX Ltd/S and related companies with MarketBeat.com's FREE daily email newsletter.